A Retrospective Cohort Study of the 2018 Angiotensin Receptor Blocker Recalls and Subsequent Drug Shortages in Patients With Hypertension

Background Valsartan was recalled by the US Food and Drug Administration in July 2018 for carcinogenic impurities, resulting in a drug shortage and management challenges for valsartan users. The influence of the valsartan recall on clinical outcomes is unknown. We compared the risk of adverse events...

Descripció completa

Dades bibliogràfiques

Autors principals:	Joshua W. Devine, Mina Tadrous, Inmaculada Hernandez, Katherine Callaway Kim, Scott D. Rothenberger, Nandita Mukhopadhyay, Walid F. Gellad, Katie J. Suda
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2024-01-01
Col·lecció:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Matèries:	drug recall drug shortages hypertension valsartan
Accés en línia:	https://www.ahajournals.org/doi/10.1161/JAHA.123.032266
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!